Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment

• Published in: American journal of human genetics Vol. 78; no. 5; pp. 804 - 814
• Main Authors: McMahon, Francis J., Buervenich, Silvia, Charney, Dennis, Lipsky, Robert, Rush, A. John, Wilson, Alexander F., Sorant, Alexa J.M., Papanicolaou, George J., Laje, Gonzalo, Fava, Maurizio, Trivedi, Madhukar H., Wisniewski, Stephen R., Manji, Husseini
• Format: Journal Article
• Language: English
• Published: Chicago, IL Elsevier Inc 01-05-2006; University of Chicago Press; Cell Press; The American Society of Human Genetics
• Subjects: Adult; Antidepressants; Antidepressive Agents - therapeutic use; Biological and medical sciences; Citalopram - therapeutic use; Depressive Disorder, Major - drug therapy; Depressive Disorder, Major - epidemiology; Depressive Disorder, Major - genetics; Female; Gene Frequency; General aspects. Genetic counseling; Genetics; Genotype; Humans; Male; Medical genetics; Medical sciences; Mental depression; Middle Aged; Phenotype; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Racial differences; Receptor, Serotonin, 5-HT2A - genetics; Sample size; Studies; Treatment Outcome; Human; Association; Prognosis; Gene; Serotonin; Variations; Antidepressant agent; Evolution; Genetics; Biological receptor
• ISSN: 0002-9297; 1537-6605
• DOI: 10.1086/503820

Depressive disorders account for a large and increasing global burden of disease. Although the condition of many patients improves with medication, only a minority experience full remission, and patients whose condition responds to one medication may not have a response to others. Individual variation in antidepressant treatment outcome is, at present, unpredictable but may have a partial genetic basis. We searched for genetic predictors of treatment outcome in 1,953 patients with major depressive disorder who were treated with the antidepressant citalopram in the Sequenced Treatment Alternatives for Depression (STAR*D) study and were prospectively assessed. In a split-sample design, a selection of 68 candidate genes was genotyped, with 768 single-nucleotide–polymorphism markers chosen to detect common genetic variation. We detected significant and reproducible association between treatment outcome and a marker in HTR2A (P range 1×10−6 to 3.7×10−5 in the total sample). Other markers in HTR2A also showed evidence of association with treatment outcome in the total sample. HTR2A encodes the serotonin 2A receptor, which is downregulated by citalopram. Participants who were homozygous for the A allele had an 18% reduction in absolute risk of having no response to treatment, compared with those homozygous for the other allele. The A allele was over six times more frequent in white than in black participants, and treatment was less effective among black participants. The A allele may contribute to racial differences in outcomes of antidepressant treatment. Taken together with prior neurobiological findings, these new genetic data make a compelling case for a key role of HTR2A in the mechanism of antidepressant action.